Mori M, Tezuka F, Chiba R, Funae Y, Watanabe M, Nukiwa T, Takahashi T
Department of Pathology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan.
Cancer. 1996 Feb 15;77(4):665-74.
In a previous study, morphometry and multivariate cluster analysis was performed on 97 lesions. These consisted of atypical adenomatous hyperplasia (AAH), considered to be an important lesion corresponding to a step of carcinogenesis for adenocarcinoma of the human lung, Clara cell type, and type 2 pneumocyte type adenocarcinomas. Although AAH and the two types of adenocarcinoma were re-classified into three clusters and AAH was defined in clear morphologic terms, the biologic nature of AAH has yet to be clarified. In the present study, immunohistochemical analysis was performed to gain a deeper understanding of the relationship between AAH and the two types of adenocarcinoma, and to compare the results with those obtained by morphometry.
The 97 lesions analyzed by morphometry were submitted to immunohistochemical analyses using antibodies against surfactant apoprotein A, urine protein 1, carcinoembryonic antigen and cytochrome P-450s (1A1-2, 2B1-2, 2E1). Also examined, as controls, were 17 lesions with adenomatous hyperplasia (AH), a non-neoplastic reactive change of bronchiolo-alveolar cells, 30 areas of normal Clara cells, and 36 areas of normal type 2 pneumocytes. The immunoreactivity was graded by introducing a semi-quantitative scoring system.
Immunohistochemically, AAHs behaved quite similarly to the lesions classified as Clara cell type or type 2 pneumocyte type adenocarcinomas. For any of the antibodies employed, no significant difference in immunoreactivity was demonstrated among these lesions.
The results suggest, in accordance with our previous morphometry, that AAH is a lesion closely related with Clara cell type and type 2 pneumocyte type adenocarcinomas, probably as their common precursor. However, the two types of adenocarcinomas, despite their characteristic morphologic features, are indistinguishable using the biological indicators applied in this study.
在之前的一项研究中，对97个病变进行了形态测量和多变量聚类分析。这些病变包括非典型腺瘤样增生（AAH），其被认为是与人类肺腺癌致癌过程中的一个阶段相对应的重要病变， Clara细胞型和II型肺泡上皮细胞型腺癌。尽管AAH和这两种类型的腺癌被重新分类为三个簇，并且AAH在形态学上有明确的定义，但其生物学性质尚未阐明。在本研究中，进行免疫组织化学分析以更深入地了解AAH与这两种类型腺癌之间的关系，并将结果与形态测量结果进行比较。
对通过形态测量分析的97个病变进行免疫组织化学分析，使用抗表面活性蛋白A、尿蛋白1、癌胚抗原和细胞色素P-450s（1A1-2、2B1-2、2E1）的抗体。作为对照，还检查了17个腺瘤样增生（AH）病变，这是细支气管肺泡细胞的一种非肿瘤性反应性变化，30个正常Clara细胞区域和36个正常II型肺泡上皮细胞区域。通过引入半定量评分系统对免疫反应性进行分级。
免疫组织化学显示，AAH的表现与分类为Clara细胞型或II型肺泡上皮细胞型腺癌的病变非常相似。对于所使用的任何一种抗体，这些病变之间的免疫反应性均未显示出显著差异。
结果表明，根据我们之前的形态测量，AAH是一种与Clara细胞型和II型肺泡上皮细胞型腺癌密切相关的病变，可能是它们的共同前体。然而，尽管这两种类型的腺癌具有特征性的形态学特征，但使用本研究中应用的生物学指标无法区分它们。
